Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the Swiss drugmaker, dragging peers down across the market.